Description
What it is
A melanocortin receptor agonist that acts on the central nervous system rather than the vascular system — sold pharmaceutically as Vyleesi for female sexual dysfunction research.
Why it’s studied
PT-141 represents a mechanistically distinct approach in sexual health research — operating through MC4 receptors in the brain rather than nitric oxide / PDE5 pathways like sildenafil.
Key research findings
-
FDA-approved efficacy data in female sexual dysfunction (Vyleesi, RECONNECT trials)
-
Documented activation of melanocortin pathways in CNS research
-
Effects independent of vascular function, unlike PDE5 inhibitors
